Biopharmaceutical company UCB reported revenue in the first quarter of 2018 was slightly lower at €1.07 billion but flat adjusted for the allergy drug divestiture in 2017.
Main products, Cimzia, Vimpat, Keppra, Briviact and Neupro drove growth in the three months with combined net sales of €839 million, -2% less year on year but at constant exchange rates it was 8% growth.
Jean-Christophe Tellier, CEO, said "As expected and reflected in our financial outlook for 2018, we see headwind from foreign exchange rates. At constant exchange rates, UCB’s growth drivers, our main products, are showing good continued growth. The label extension for Cimzia enable us to create further value for our patients. Our promising pipeline, now encompassing 13 new molecular entities, is making good progress. Also, our research platform is strengthened by Element Genomics in the U.S. Our epilepsy portfolio will be strengthened with the addition of midazolam nasal spray."
UCB confirmed its financial outlook for the full year 2018 with revenue expected to reach €4.5 to €4.6 billion and core earnings per share of €4.30 to €4.70